Bloomberg / Contributor / Getty Images Merck agreed to pay Daiichi Sankyo $5.5 billion to jointly develop and commercialize three of its candidate cancer drugs. Merck could pay up to $22 billion ...

MUMBAI, April 20 (Reuters) - Japan's Daiichi Sankyo Company Ltd is selling shares worth up to $3.6 billion in Indian drugmaker Sun Pharmaceutical Industries Ltd, setting it on course to retreat ...

Daiichi Sankyo's once-daily oral factor Xa inhibitor edoxaban is as ... the Academic Medical Center in Amsterdam predicted that the findings will “shake things up a bit” in the new oral anticoagulant ...

Dato-DXd Is Up Next, With A Significant Pipeline To Follow The next major revenue contributor from Daiichi Sankyo’s ADC pipeline is likely to be Dato DXd, an ADC that targets TROP-2 and has ...

Oct 19 (Reuters) - Daiichi Sankyo 4568.T and Merck MRK.N have entered into an agreement worth up to $22 billion to develop and commercialize three of Daiichi Sankyo's DXd antibody drug conjugate ...